Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Glioma 3Myelodysplastic Syndromes 2Leukemia, Myeloid, Acute 2Diffuse Intrinsic Pontine Glioma 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Obesity 1Neoplasm Metastasis 1Meningioma 1Fallopian Tube Neoplasms 1Endometrial Neoplasms 1Disease 1Carcinosarcoma 1

Interventions

Paclitaxel 40Carboplatin 34Bevacizumab 29liposomal doxorubicin 20Specimen Handling 18Taxes 17olaparib 16Magnetic Resonance Spectroscopy 16pembrolizumab 15Gemcitabine 15Topotecan 13Immunoglobulin G 11Disulfides 11Biopsy 11mirvetuximab soravtansine 8niraparib 7Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × TIC10 compound × 1 year × Clear all
NCT04055649 2025-06-18

ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer

Barbara Ann Karmanos Cancer Institute

Phase 2 Recruiting
62 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡